Beta Drugs Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Beta Drugs Limited Pharmaceutical Export Portfolio Dataset — 17 Products, $7.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Beta Drugs Limited — Pharmaceutical Exporter Profile (2026) | 17 Products, $7.8M Trade | TransData Nexus

Who is Beta Drugs Limited? — Company Overview & Market Position

Beta Drugs Limited, established in 1985, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of oncology and cosmeceutical products. The company is headquartered in Panchkula, Haryana, India, with its registered office located at Village Nandpur, Baddi, Himachal Pradesh 174101. Incorporated as a private limited company on September 21, 2005, it was subsequently converted into a public limited company on August 11, 2017. The Corporate Identification Number (CIN) assigned to Beta Drugs Limited is L24230HP2005PLC028969. As of the latest available data, the company has an authorized share capital of ₹114 million and a paid-up capital of ₹101.36 million. Beta Drugs Limited is listed on the National Stock Exchange of India under the ticker symbol BETA. The company employs approximately 399 individuals. For more information, Beta Drugs Limited maintains an official website at betadrugslimited.com.

What Does Beta Drugs Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Linagliptin$2.5M 2Sitagliptin$2.4M 3Carboplatin$1.1M 4Capecitabine$708.5K 5Mercaptopurine$232.5K 6Vildagliptin$193.9K 7Cisplatin$180.9K 8Lenalidomide$110.3K 9Etoposide$96.4K 10Fludarabine$61.8K 11Temozolomide$43.1K 12Vincristine$29.8K

Beta Drugs Limited Therapeutic Categories — 5 Specializations

Beta Drugs Limited operates across 5 therapeutic categories, with Advanced Diabetes Medications (34.9%), Diabetes & Endocrine (31.0%), Oncology (18.1%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 90% of total exports.

Advanced Diabetes Medications

2 products · 34.9% · $2.7M

Diabetes & Endocrine

1 products · 31.0% · $2.4M

Oncology

4 products · 18.1% · $1.4M

Advanced Oncology

9 products · 15.7% · $1.2M

Cardiovascular

1 products · 0.3% · $26.2K

Product Portfolio — Top 17 by Export Value

Beta Drugs Limited exports 17 pharmaceutical products across 5 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Linagliptin	Advanced Diabetes Medications	$2.5M	124	65.1%	1
2	Sitagliptin

Key Metrics

Total Trade$7.8M

Products17

Shipments719

Categories5

#1 Rankings2

Top 5 Concentration89.6%

Top Categories

Advanced Diabetes Medications34.9%

Diabetes & Endocrine31.0%

Oncology18.1%

Last updated: March 28, 2026

Beta Drugs Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Beta Drugs Limited operates state-of-the-art manufacturing facilities in Baddi, Himachal Pradesh, India. These facilities are equipped to produce a diverse range of pharmaceutical formulations, including oncology products, cosmeceuticals, and active pharmaceutical ingredients (APIs). The company's manufacturing capabilities encompass various dosage forms such as tablets, capsules, syrups, and injections. Specific details regarding production capacities and specialized manufacturing processes are not publicly disclosed.

Beta Drugs Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Beta Drugs Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has received approval for several Abbreviated New Drug Applications (ANDAs), allowing it to market generic versions of branded drugs in the U.S. market. Additionally, Beta Drugs Limited has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, and there are no records of Form 483 observations, warning letters, or import alerts, indicating compliance with FDA regulations.

2WHO & EU GMP

Beta Drugs Limited has achieved prequalification from the World Health Organization (WHO), affirming that its products meet international quality standards. The company holds European Union Good Manufacturing Practice (EU GMP) certificates, demonstrating adherence to EU regulations for pharmaceutical manufacturing. These certifications enhance Beta Drugs Limited's credibility and facilitate access to global markets, including the European Union.

3CDSCO & Indian Regulatory

Beta Drugs Limited possesses manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has obtained approvals from state drug controllers for its manufacturing facilities, ensuring compliance with regional regulations. Beta Drugs Limited has secured export No Objection Certificates (NOCs), authorizing the export of its pharmaceutical products to various international markets.

4Recent Regulatory Actions

As of March 28, 2026, there are no publicly available records indicating that Beta Drugs Limited has received any Form 483 observations, warning letters, or import alerts from regulatory authorities such as the FDA. This absence suggests that the company maintains a strong compliance record with regulatory standards.

TransData Nexus Research · FDA Orange Book, WHO PQ database, EMA GMP registry, CDSCOMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Supplier Matching: Beta Drugs Limited identified across shipments using name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
3.Market Share: Calculated per product as Beta Drugs Limited's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 719 individual customs records matching Beta Drugs Limited.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

17 Products Tracked

5 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Beta Drugs Limited

Beta Drugs Limited — Export Portfolio & Destination Treemap

Who is Beta Drugs Limited? — Company Overview & Market Position

What Does Beta Drugs Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Beta Drugs Limited Therapeutic Categories — 5 Specializations

Product Portfolio — Top 17 by Export Value

Key Metrics

Top Categories

Beta Drugs Limited — Corporate Profile & Information

1Corporate Overview

2Manufacturing Facilities

Top Export Routes

Related Analysis

Need Detailed Data?

3Key Leadership

Where Does Beta Drugs Limited Export? — Destination Intelligence

1Regulated Markets

2Emerging Markets

3Geographic Strategy

Beta Drugs Limited — Manufacturing & Regulatory Profile

1FDA Status

2WHO & EU GMP

3CDSCO & Indian Regulatory

4Recent Regulatory Actions

Beta Drugs Limited — Competitive Positioning Among Indian Pharma Exporters

1Competitive Landscape

2Key Differentiators

3Strategic Position

Buyer Due Diligence Brief — Evaluating Beta Drugs Limited as a Supplier

1Supplier Assessment

2Certifications to Verify

3Due Diligence Checklist

Frequently Asked Questions — Beta Drugs Limited

How many pharmaceutical products does Beta Drugs Limited export from India?

What is Beta Drugs Limited's total pharmaceutical export value?

In which products is Beta Drugs Limited the #1 Indian exporter?

What therapeutic categories does Beta Drugs Limited cover?

Get Full Beta Drugs Limited Export Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology